Allogene Therapeutics (ALLO) Operating Income: 2019-2025
Historic Operating Income for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$44.9 million.
- Allogene Therapeutics' Operating Income rose 37.44% to -$44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$227.4 million, marking a year-over-year increase of 23.64%. This contributed to the annual value of -$273.2 million for FY2024, which is 16.64% up from last year.
- Per Allogene Therapeutics' latest filing, its Operating Income stood at -$44.9 million for Q3 2025, which was up 20.98% from -$56.8 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Operating Income ranged from a high of $1.7 million in Q4 2021 and a low of -$99.1 million during Q1 2023.
- Over the past 3 years, Allogene Therapeutics' median Operating Income value was -$69.5 million (recorded in 2024), while the average stood at -$69.8 million.
- Per our database at Business Quant, Allogene Therapeutics' Operating Income soared by 102.46% in 2021 and then tumbled by 5,747.04% in 2022.
- Allogene Therapeutics' Operating Income (Quarterly) stood at $1.7 million in 2021, then crashed by 5,747.04% to -$96.4 million in 2022, then climbed by 11.71% to -$85.1 million in 2023, then increased by 28.93% to -$60.5 million in 2024, then spiked by 37.44% to -$44.9 million in 2025.
- Its last three reported values are -$44.9 million in Q3 2025, -$56.8 million for Q2 2025, and -$65.2 million during Q1 2025.